British Journal of Cancer Management

This item requires a subscription.

The sequencing of treatments for multiple myeloma
BJCM, Volume 2, Number 3.

The last ten years have seen dramatic changes in our approach to the treatment of multiple myeloma. Initial comparisons of combination chemotherapy against standard melphalan and prednisolone did not seem to show any therapeutic advantage. However, more recently, it has been confirmed that autologous trans-plantation following high-dose melphalan offers significant advantages in terms of both progression-free and overall survival.1 Consequently, autologous stem cell trans-plantation has become the central plank of the management of younger, biologically fit patients with multiple myeloma.

To view this item, select one of the options below:

	Purchase access
	In order to view articles you will need to pay a subscription for 24-hour access. You can view all articles on this site during the subscription period. Please click here to subscribe.

	Sign in
	If you are already have a subscription, please sign in here.
	email address
	Password
	Forgotten your password?

	Important
	All the articles are in PDF format.
	To view the articles you will need Adobe Acrobat Reader.
	To download a copy, free of charge, please click here.

	Help
	If you need help accessing this site, please click here.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.
Copyright (©) 2010 Hayward Group Ltd. The title British Journal of Cancer Management is the property of Hayward Group Ltd and, together with the content, is bound by copyright. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk